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Abstract: Codium fragile and Chondrus crispus are, respectively, green and red seaweeds 
which are abundant along the North Atlantic coasts. We investigated the chemical 
composition and antiviral activity of enzymatic extracts of C. fragile (CF) and C. crispus 
(CC). On a dry weight basis, CF consisted of 11% protein, 31% neutral sugars, 0.8% 
sulfate, 0.6% uronic acids, and 49% ash, while CC contained 27% protein, 28% neutral 
sugars, 17% sulfate, 1.8% uronic acids, and 25% ash. Enzyme-assisted hydrolysis improved 
the extraction efficiency of bioactive materials. Commercial proteases and carbohydrases 
significantly improved (p ≤ 0.001) biomass yield (40%–70% dry matter) as compared to 
aqueous extraction (20%–25% dry matter). Moreover, enzymatic hydrolysis enhanced the 
recovery of protein, neutral sugars, uronic acids, and sulfates. The enzymatic hydrolysates 
exhibited significant activity against Herpes simplex virus (HSV-1) with EC50 of  
77.6–126.8 μg/mL for CC and 36.5–41.3 μg/mL for CF, at a multiplicity of infection 
(MOI) of 0.001 ID50/cells without cytotoxity (1–200 μg/mL). The extracts obtained from 
proteases (P1) and carbohydrases (C3) were also effective at higher virus MOI of  
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0.01 ID50/cells without cytotoxity. Taken together, these results indicate the potential 
application of enzymatic hydrolysates of C. fragile and C. crispus in functional food and 
antiviral drug discovery. 




Viruses cause life-threatening diseases such as hepatitis, influenza, HIV-AIDS, ebola, and herpes. 
Hence, there is a concerted effort to discover antiviral agents to control infection and the spread of 
infectious diseases. The Herpes simplex virus (HSV) is a double-stranded DNA-enveloped virus, and a 
common human pathogen. There are two strains: HSV-Type 1 (HSV-1) and HSV-Type 2 (HSV-2). 
HSV-1 is frequently associated with oral and facial infections and encephalitis, whereas HSV-2 causes 
genital tract infections [1]. In the United States, 60%–85% of adults, by the age of 60 years, have 
HSV-1 antibodies, and 6%–50% at the age of 40 have HSV-2 antibodies in their blood [2]. HSV enters 
the host through mucous membranes or skin lesions into the orolabial epithelial cells. This entry is 
mediated by viral envelope proteins, such as viral glycoproteins gB, gC, gD, gH, and gL. HSV 
adsorption by target cells involves the interaction between cell-surface heparin sulfate (HS) and viral 
glycoprotein. Upon successful adsorption, the virus replicates by rapid cell-to-cell multiplication 
within the epithelial cells. Further, the virus is transported by infected sensory neuritis to trigeminal 
ganglia, where it establishes long-term latency within infected sensory neurons [3–5]. Recurrent 
infections with HSV are more frequent in people with acquired immune deficiency (AIDS) and can 
lead to high mortality. HSV infection is one of the first opportunistic infections in AIDS patients. 
Therefore, its control is considered to be a primary approach in the clinical management of HIV [6–8]. 
Similarly, primary or recurrent HSV in the genital tract of a mother can lead to neonatal HSV 
infections. In the United States, incidences of neonatal HSV are common (8 to 60 per 100,000). A 
newborn child with HSV infection is predisposed to acute meningoencephalitis, neurological disorders, 
skin and eye lesions, and disseminated diseases [9,10]. HSV-associated diseases are also recurrent in 
allogeneic bone marrow patients (70%–80%) and solid organ transplant patients (32%–53%) [11,12]. 
The common anti-HSV drugs include acyclic nucleosides Acyclovir (ACV). Acyclovir is a 
guanosine analog that interferes with viral DNA synthesis and prevents chain elongation and viral 
replication [13]. Recently, other nucleoside analogs, such as Penciclovir, and Ganciclovir and their 
derivatives valacyclovir and famciclovir, all of which interfere with viral DNA replication, have been 
introduced for human anti-HSV treatments [14,15]. Although acyclovir and its derivatives are very 
effective antiherpes drugs, there is an emergence of drug-resistant mutants due to prolonged use of this 
drug [16]. Cidofovir, which is commonly used for the treatment of acyclovir- and foscarnet-resistant 
HSV infections [14], is nephrotoxic and therefore its use is restricted to patients with normal renal 
functions. Therefore, there is an immediate need for the development of novel antiherpetic agents [8]. 
Antiviral chemotherapy currently faces several obstacles including: toxicity of therapeutic molecules, 
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interference with normal cellular metabolism, genetic variability (source of antiviral resistant mutants), 
and the incurable nature of latent infections. 
More than 70% of the world’s surface is covered with oceans, teeming with marine organisms 
containing diverse bioactive compounds. Marine macroalgae, commonly referred to as seaweeds, are 
good sources of food and raw materials for cosmetic and the pharmaceuticals industry, and also have 
agricultural uses [17]. Seaweeds are rich in novel bioactive polysaccharides showing antimicrobial, 
antioxidant and antiviral activities. The edible red macroalga (Rhodophyta) Chondrus crispus is 
abundant along parts of the North Atlantic coast, where it is collected for carrageenan extraction [18]. 
Selected strains are also commercially cultivated on-land by Acadian Seaplants Limited in Nova  
Scotia [19,20]. Carrageenans and galactans are the main matrix polysaccharides of red seaweeds. 
These polysaccharides are formed by alternating units of 3-linked β-D-galactopyranosyl and 4-linked 
α-D/L-galactopyranosyl and have been shown to block viral replication and adsorption to the host cell 
surface [21–25]. Codium fragile, is an invasive green alga in Nova Scotia. It is now widely distributed 
along the east coast of North America [26], as well as in Europe. In Japan, C. fragile is used as food, 
and it is also used to treat diseases such as enterobiasis, dropsy, and dysuria, as documented in Asian 
medical textbooks [8]. Sulfated polysaccharides, such as glucuronic acid, iduronic acid, and rhamnan 
sulfates isolated from green seaweeds, including Ulva, Enteromorpha, and Monostroma attisimum, have 
been reported previously to have antiviral activities [13]. Therefore, seaweed-derived polysaccharides 
can be potential sources of functional bioactives, effective against viruses. Generally, the bioactive 
components of seaweeds are extracted using solvents and strong alkali. In recent years, enzyme-
assisted extraction has gained attention as an effective tool to improve the extraction yield of bioactive 
compounds from seaweeds [27]. Additionally, this extraction method has been reported to increase the 
bioavailability of antiviral compounds such as polysaccharides, diterpenes, or glycolipids present in 
the seaweeds. Moreover, enzyme-assisted extraction is a solvent-free, eco-friendly, and cost-effective 
extraction method [2,28]. 
The aim of this study was to examine the use of three commercial carbohydrases and proteases to 
improve the extraction efficiency of bioactive materials from the selected red and green seaweeds,  
C. crispus (multiaxial filamentous tissue) and C. fragile (a coenocytic tissue), respectively. The 
recovery of chemical compounds using different enzymes was analyzed and then tested for antiviral 
activity against HSV-1 by a cytotoxic assay based on cell viability. 
2. Results 
2.1. Composition of Acid Hydrolysis Extract 
The chemical composition of Chondrus crispus (CC) was significantly different from that of 
Codium fragile (CF) (Table 1). Dried CC contained 27.2% ± 1.4% protein, 17.6% ± 0.1% sulfates, and 
1.8% ± 0.07% uronic acid. The dried CF samples contained 11.7% ± 0.3% proteins, 0.8% ± 0.1% 
sulfates, and 0.6% ± 0.01%uronic acid. The ash and neutral sugar content of the extract of CF was 
significantly (p ≤ 0.0001, n = 9) higher (49.9% ± 0.2%, 31.1% ± 0.4%) than that of CC (25% ± 0.3%, 
28.8% ± 0.5%). CC had higher (p ≤ 0.0001, n = 9) proteins, sulfates, and uronic acids. The protein, 
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sugars, sulfates, and uronic acid contents of 2 h hydrolysate were higher than those of 5 h hydrolysates  
(data not shown).  
Table 1. Chemical composition of Chondrus crispus (CC) and Codium fragile (CF)  
(raw matter after 2 h of hydrolysis) 1. 
Algae (Freeze-Dried) 2 Proteins Neutral Sugars Sulfate Groups Uronic Acids Ash 
Chondrus crispus 27.2 ± 1.4 a 28.8 ± 0.5 a 17.6 ± 0.1 a 1.8 ± 0.07 a 25 ± 0.3 b 
Codium fragile 11.7 ± 0.3 b 31.1 ± 0.4 b 0.8 ± 0.1 b 0.6 ± 0.01 b 49.9 ± 0.2 a 
P-value ≤0.0001 0.028 ≤0.0001 ≤0.0001 ≤0.0001 
1 In percentage dry matter hydrolysate (1 mg/mL); 2 Values are means ± SD (standard deviation) for each 
chemical analysis (nine replicates per treatment). Values with different superscript letters are significantly 
different (p < 0.05). 
2.2. Biomass Yield 
The repartitioning rate of algal dry matter is shown in Figure 1. Enzymatic extraction significantly 
increased the dry matter yield. In CF, the extraction yields with carbohydrases (C1) and proteases (P1) 
was 47.8% ± 3.5% and 46.6% ± 2.5%, respectively, which were higher (p ≤ 0.001) than control (water 
blank, 22.4% ± 1.9%). With CC, the higher percentage (p ≤ 0.001) of dry matter was obtained in 
supernatants treated with carbohydrases C1 and C3 (73.4% ± 3.3% and 71.2% ± 7.7%, respectively). 
Water extraction (water blank), under similar conditions of temperature and duration, showed lower 
dry matter yield (CF, 22.4% ± 1.9% and CC, 24.7% ± 2.1%, respectively). This indicated that the use 
of enzymes increased the extraction efficiency, in comparison to a water extraction.  
  
Figure 1. Cont. 




Figure 1. The repartitioning rate of algal dry matter (percentage dry matter yield) obtained 
with enzymatic hydrolysis of (a) Codium fragile (CF) and (b) Chondrus crispus (CC). 
Values with different superscript letters are significantly different (p < 0.05). Values 
represent mean ± standard deviation from three independent experiments (n = 9). P1: 
protease 1; C1: carbohydrases 1; C2: carbohydrases 2; C3: carbohydrases 3. 
2.3. Chemical Analysis of Enzymatic Hydrolysates 
The recovery of chemical fractions from the enzymatic hydrolysis of the two seaweeds is shown in 
Figures 2–6. The percentage yield of each chemical compound in the hydrolysates is based on their dry 
weight percentage, obtained from the initial algal sample. Of all the chemical components, 
carbohydrases exhibited the highest percentage of dry matter in the hydrolysates. 
2.3.1. Proteins 
Recovery of protein in the enzymatic extract of C. crispus was higher than that for C. fragile 
(Figure 2a,b). In C. crispus, the percentage recovery was highest with C1 (7.1% ± 0.3%) and ranged 
between 4.1% ± 0.4% and 5.8% ± 0.5% for other enzymes; this was significantly higher (p ≤ 0.05) 
than the control (water, 1.8% ± 0.1%). Similarly, with C. fragile, the percentage yield with enzymes 
(P1: 2.9% ± 0.1% and C1: 2.6% ± 0.2%) was higher than that of the control (1.4% ± 0.1%)  
(Figure 2b). Overall, the three carbohydrases were the most effective enzymes for the protein recovery 
(Figure 2a,b). 
Dry matter (% dm algae) 




Figure 2. Total protein content in enzymatic hydrolysates of (a) Codium fragile (CF) and 
(b) Chondrus crispus (CC). Values with different superscript letters are significantly 
different (p < 0.05). Values represent mean ± standard deviation from three independent 
experiments (n = 9). P1: protease 1; C1: carbohydrases 1; C2: carbohydrases 2;  
C3: carbohydrases 3.  
2.3.2. Neutral Sugars 
Enzymatic extraction was an effective method to improve recovery of neutral sugars (Figure 3a,b). The 
percentage of neutral sugar in the enzymatic hydrolysates ranged from 9.3% ± 0.2% (C2) to  
21.9% ± 0.4% (C3) in C. crispus and 4.3% ± 0.2% (C1) to 5.4% ± 0.3% (P1) in C. fragile. Overall, the 
neutral sugars content extracted with carbohydrases was the highest. 
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Figure 3. Content of neutral sugars in enzymatic hydrolysates from the two seaweeds (a) 
Codium fragile (CF) and (b) Chondrus crispus (CC). Values with different superscript 
letters are significantly different (p < 0.05). Values represent mean ± standard deviation 
from three independent experiments (n = 9). P1: protease 1; C1: carbohydrases 1;  
C2: carbohydrases 2; C3: carbohydrases 3. 
2.3.3. Uronic Acid 
The concentration of uronic acid was significantly higher (p ≤ 0.05) in the enzymatic extracts as 
compared to the aqueous controls (Figure 4a,b). In C. crispus, the uronic acid concentration was  
0.8% ± 0.0% (P1), 1.2% ± 0.0% (C1), 1.0% ± 0.0% (C2), and 1.4% ± 0.0% (C3) (Figure 4a). For  
C. fragile, the uronic acid content was 0.23% ± 0.0% and 0.1% ± 0.0% with C1 and P1, respectively 
(Figure 4b). 
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Figure 4. Uronic acids in enzymatic hydrolysates of (a) Codium fragile (CF) and  
(b) Chondrus crispus (CC). Values with different superscript letters are significantly 
different (p < 0.05). Values represent mean ± standard deviation from three independent 
experiments (n = 9). P1: protease 1; C1: carbohydrases 1; C2: carbohydrases 2;  
C3: carbohydrases 3.  
2.3.4. Sulfates 
The effect of enzyme treatments on the extraction of the sulfated groups is shown in Figure 5a,b. As 
some red seaweeds are rich in sulfated polysaccharides, the percentage yield of sulfates was higher in 
C. crispus, as compared to C. fragile. The percentage of sulfated groups in C. crispus enzymatic 
extracts was 8.4% ± 0.1% (P1), 11.7% ± 0.1% (C1), 8.0 ± 0.1 (C2), and 11.0 ± 0.1 (C3), respectively. 
For C. fragile, no significant differences were observed in the extraction yield of sulfates with the use 
of P1 (0.5% ± 0.0%) and C1 (0.5% ± 0.0%), as compared to the water extract (0.4% ± 0.1%). 
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Figure 5. Sulfate groups in the enzymatic hydrolysates of (a) Codium fragile (CF) and 
(b) Chondrus crispus (CC). Values with different superscript letters are significantly 
different (p < 0.05). Values represent mean ± standard deviation from three independent 
experiments (n = 9). P1: protease 1; C1: carbohydrases 1; C2: carbohydrases 2;  
C3: carbohydrases 3.  
2.3.5. Ash 
The percentage yield of ash in the enzymatic hydrolysates was higher than in the water extract 
(Figure 6a,b). The enzymatic hydrolysates of C. fragile had higher ash content than C. crispus. For  
C. fragile, the percentage dry matter yield of ash was higher (p ≤ 0.05) with P1 (35.9% ± 0.3%) than 
C1 (29.3% ± 0.1%). Moreover, C. crispus had a lower yield of ash in the treatments, as well as in their 
water extract (Figure 6b). For C. crispus, the carbohydrases were more effective in extracting ash from 
the biomass than the proteases (Figure 6b). 
Sulfate groups (% dm hydrolysate) 
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Figure 6. Total ash content in the enzymatic hydrolysates of (a) Codium fragile (CF) and 
(b) Chondrus crispus (CF). Values with different superscript letters are significantly 
different (p < 0.05). Values represent mean ± standard deviation from three independent 
experiments (n = 9). P1: protease 1; C1: carbohydrases 1; C2: carbohydrases 2;  
C3: carbohydrases 3.  
2.4. Carbohydrate Composition 
The monosaccharide profiles of the enzymatic hydrolysates of C. crispus and C. fragile are shown 
in Table 2. Extracts were composed of galactose, glucose, and mannose as major sugars and trace 
quantities of arabinose and xylose were also identified. Xylose was absent in CF extracts and relatively 
low percentage of arabinose was detected in CC extracts. In CC, the higher percentages of glucose and 
mannose (46.1% ± 8.6 and 11.7% ± 4.9%, respectively) were detected in the C3 hydrolysate, whereas 
the percentage of galactose was higher in the control (water blank 83.6% ± 0.4%). In CF, the highest 
percentage of glucose was found in proteolytic extract (P1, 55.9% ± 0.4%) and galactose, mannose, 
Ash (% dm hydrolysate) 
Ash (% dm hydrolysate) 
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and arabinose were higher in the control (water blank: 20.06% ± 0.17%, 15.3% ± 0.2%, and  
4.5% ± 0.1%, respectively). Besides the detectable monosaccharides, several unknown peaks were 
observed in CC and CF chromatograms; these were denoted as unknown sugars (mol%). Higher 
percentages of unknown sugars were detected in CC and CF, the enzymatic hydrolysates (Table 2). 
Peaks for sugars such as rhamnose, fructose, ribose, glucoheptose, and glucuronic acid were detected 
at very low levels and, therefore, added to the total for unknown sugars. The polysaccharide content  
of CC ranged from 40% to 75%), thus indicating that only half of the sugars were being accessed  
in hydrolysis. 
Table 2. Monosaccharide composition (mol%) in the enzymatic hydrolysates 1. 
Treatments Arabinose Galactose Glucose Mannose Xylose Other Sugars 
CC (Blank) 0.00 83.63 ± 0.42 1.23 ± 0.19 1.46 ± 0.04  2.57 ± 0.05 10.22 ± 0.31 
CC (P1) 0.19 ± 0.01 75.24 ± 1.88 3.13 ± 0.27 1.24 ± 0.71 1.64 ± 0.90 17.95 ± 1.18 
CC (C1) 0.07 ± 0.00 73.11 ± 0.39 1.44 ± 0.02 1.72 ± 0.03 2.48 ± 0.06 19.59 ± 0.40 
CC (C2) 0.06 ± 0.00 74.87 ± 0.32 1.81 ± 0.23 1.11 ± 0.08 2.45 ± 0.07 18.98 ± 0.09 
CC (C3) 3.19 ± 0.44 12.94 ± 2.39 46.05 ± 8.66 11.69 ± 4.93 0.00 28.50 ± 1.97 
CF (Blank) 4.49 ± 0.04 20.06 ± 0.17 53.52 ± 0.14 15.30 ± 0.16 0.00 5.85 ± 0.53 
CF (P1) 2.48 ± 0.17 10.80 ± 0.77 55.92 ± 0.45 7.25 ± 1.33 0.00 23.21 ± 1.90 
CF (C1) 0.12 ± 0.00 78.10 ± 0.37 1.14 ± 0.09 5.45 ± 0.06 0.00 14.27 ± 0.33 
1 Values are means for each treatment (Trt) group (CC: Chondrus crispus; CF: Codium fragile; P1: protease 1; C1: 
carbohydrases 1; C2: carbohydrases 2; C3: carbohydrases 3). Values represent mean ± standard deviation from three 
independent experiments (n = 3). 
2.5. Antiviral Activity and Cytotoxicity 
The enzymatic extracts were tested for their antiviral activity against the Herpes simplex virus Type 1 
(HSV-1) using Vero cell lines. Additionally, the cytotoxicity of enzymatic extracts to Vero cells was 
also evaluated. After three days of treatment, no cytotoxicity was observed in extracts of either of the 
seaweeds tested (Table 3). The enzymatic extracts exhibited significantly higher (p < 0.0001) antiviral 
activity at multiplicity of infection (MOIs) of 0.001 ID50/cells (12–45 x acyclovir) and 0.01 ID50/cells 
(3–8 x acyclovir) (Table 3). Maximum inhibition of viral activity was observed in the enzymatic 
extract of CF (36.5 ± 10.3 μg/mL). In CC, the extracts obtained with P1 exhibited effective antiviral 
effect (77.6 ± 9.6 μg/mL). No anti-HSV-1 activity was observed in CC hydrolysates obtained from 
enzymatic extraction with C1 and C2 at a multiplicity of infection of 0.01 ID50/cells (Table 3). At the 
same MOI, all the extracts from C. fragile showed strong HSV-1 inhibition, with P1 being the most 
effective (Table 3). 
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Table 3. Evaluation of anti-HSV activity of enzymatic hydrolysate from Codium fragile 
and Chondrus crispus by neutral red dye method at MOI = 0.001 and 0.01 ID50/cells 1. 
Treatments 2 MOI = 0.001 ID50/Cells MOI = 0.01 ID50/Cells
 
 CC50 (μg/mL) EC50 (μg/mL) 2 CC50 (μg/mL) EC50 (μg/mL) 2 
Drug (Acyclovir) >200 2.9 ± 0.5 d >200 20.2 ± 8.0 c 
CC (Blank) >200 129.7 ± 0.5 a >200 >200 
CC (P1) >200 77.6 ± 9.6 b >200 161.1 ± 4.3 a 
CC (C1) >200 103.3 ± 12.1 b >200 >200 
CC (C2) >200 126.8 ± 9.0 a >200 >200 
CC (C3) >200 109.3 ± 9.6 b >200 178.8 ± 12.3 a 
CF (Blank) >200 52.3 ± 10.7 c >200 144.3 ± 2.1 a 
CF (P1) >200 36.5 ± 10.3 c >200 63.2 ± 11.4 b 
CF (C1) >200 41.3 ± 5.6 c >200 82.8 ± 13.9 b 
P-value <0.0001 <0.0001 
1 MOI: Multiplicity of infection ID50/cells, ratio (Virus titer)/(cell number/mL); cytotoxic concentration 
(CC50): The concentration of a compound required to reduce cell viability by 50% compared to the control. 
P1: protease 1; C1: carbohydrases 1; C2: carbohydrases 2; C3: carbohydrases 3; effective concentration (EC50): 
the concentration required to achieve 50% protection against virus-induced cytopathy; 2 Values represent 
mean ± standard deviation from three independent experiments (n = 12). Values with different superscript 
letters are significantly different (p < 0.05).  
3. Discussion 
In this study, we studied the antiviral activity of enzymatic extracts of the selected, cultivated red 
seaweed C. crispus and green seaweed C. fragile. In recent years, the use of enzyme-assisted 
extraction has gained much attention for its improved recovery of biologically active components from 
seaweeds [29]. Wang et al. (2010) [30] investigated the use of proteases and carbohydrases to improve 
the yield of polyphenols and other antioxidants from the red seaweed Palmaria palmata. In the present 
study, a proximate analysis was conducted to aid selection of appropriate enzymes for hydrolysis. The 
proximate composition of C. crispus and C. fragile showed similar profiles of protein, uronic acid, and 
neutral sugar content (Table 1), as reported previously in other seaweeds: Porphyra columbina, 
Palmaria palmata, and Ulva sp. [31,32]. Fleurence (1999) [33] reported that the crude protein content 
of dried seaweeds ranged between 11% and 28%, and the present study showed similar levels of 
protein (Table 1). The ash content of C. crispus and C. fragile was notably higher than other red and 
green seaweed species, such as Sphaerococcus coronopifolius, Boergeseniella thuyoides, Gracilaria 
cervicornis, Hypnea charoides, H. japonica, and Ulva lactuca [23,34–36]. This may be due to the 
differences in species, geographical location, and conditions such as temperature, salinity, and nutrient 
availability. Previous studies showed that the water extract from C. fragile contained about 70% 
carbohydrates (mainly mannose), and 7%–8% sulfated arabinogalactans [37]. However, in the present 
study, the neutral sugar percentage in the acid hydrolysates of C. fragile was comparatively low (Table 1). 
In general, bioactive compounds are extracted with water or organic solvents. However, the 
extraction efficiency for these methods ranges from 8% to 30% of the algal dry yield [38]. Moreover, 
bioactive compounds in the seaweed cell matrix are usually present at very low concentrations. 
Alternative extraction techniques, such as enzymolysis and microwave-assisted extractions, have been 
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employed to improve the yield of extracts [39,40]. Enzyme-assisted extraction (EAE) is an alternative 
to conventional solvent based methods, due to its high catalytic efficiency, high specificity, and mild 
reactive conditions [41,42]. Previously, enzyme-assisted extraction has been extensively used to 
extract bioactives from red and green algae [30,43]. In the present study, carbohydrases (C1) and 
proteases (P1) were used. However, polysaccharides and gelling agents present in the cell wall of  
C. crispus may have interfered with the extraction process (data not shown). Therefore, the extraction 
procedure was modified (1:200 mL of water) and two additional carbohydrases (C2 and C3) were used 
to enhance the extraction of bioactives from C. crispus. However, it would have been preferable to use 
these two carbohydrases in the extraction study of CF for better comparison. The results indicated that 
enzymes P1, C1, C2, and C3 improved the extraction efficiency (i.e., dry matter yield) two- to 
threefold as compared to water extraction (Figure 1). Fleurence et al. (1995) [44] studied the effect of 
polysaccharidases (i.e., κ-carrageenase, β-agarase, xylanase, and cellulase) on the extraction of protein 
from three red seaweeds—C. crispus, Gracilaria verrucosa, and Palmaria palmata. They concluded 
that Chondrus crispus/carrageenase + cellulase and Gracilaria verrucosa/agarase + cellulase combinations 
resulted in a ten- and three-fold increase in protein extraction, respectively [44]. Similarly, previous 
studies have reported higher dry matter yields from red seaweeds such as Solieria chordalis and P. 
palmata using carbohydrases [2,31]. In red seaweeds including C. crispus, the cell wall-bound 
polysaccharide serves as a substrate for carbohydrases [45]. This correlated to the higher dry matter 
yield obtained with carbohydrases C1 and C3 from C. crispus. Denis et al. (2009) [46] used 
polysaccharidases (Onozuka R-10 cellulase, agarose, and Ultraflo L mixture) to assess metabolite 
extraction from the red seaweed Grateloupia turuturu. The enzymatic treatment resulted in better 
degradation of Grateloupia tissue and a greater release of reducing carbohydrates [46]. Hardouin et al. 
(2014) [2] proposed the use of an enzymatic extraction to increase the yield of antiviral compounds 
from selected French red, green, and brown seaweeds, viz., Solieria chordalis, Ulva sp., and 
Sargassum muticum. The use of proteases and carbohydrases resulted in higher yields of protein, 
neutral sugars, and polyphenols [2]. Similarly, the present study results were in agreement i.e., in 
comparison to the water extraction, enzymatic extraction resulted in higher recovery of proteins  
(2–5 x), neutral sugars (2–12 x), uronic acids (2–4 x) and sulfated groups (2–3 x) from the seaweeds  
C. fragile and C. crispus (Figures 2–6). 
Several seaweed polysaccharides, such as carrageenans, sulfate proteoglycans, dextran sulfates, 
alginate polysaccharide, and sulfated fucans, have been shown to exhibit antiviral activities against 
human papillomavirus (HPV), influenza A virus (IAV), and human herpes virus HSV-1 and  
HSV-2 [47–49]. Additionally, UVA-photosensitizers from seaweeds have also been identified as 
virucidal against RNA- and DNA-enveloped viruses. Hudson et al. (1999) [50] determined the 
antiviral activity of extracts from 13 Korean seaweeds. They showed that an organic extract of  
C. fragile was capable of inhibiting three viruses (herpes simplex, HSV; Sindbis, SINV; and polio) [50]. 
The present experiments confirm the antiviral potential of the enzymatic extracts of C. crispus and  
C. fragile. All extracts (enzymatic and water control) had some antiviral activity at  
MOI = 0.001 ID50/cells (Table 3). The fractions obtained with carbohydrases (C1 and C3) and 
proteases (P1) were the most effective for C. crispus. This could be due to the difference in the ability 
of enzymes to extract sulfates from this red, multiaxial seaweed. Previously it has been shown that the 
antiviral activity of some seaweed extracts were due to its sulfates that form polysaccharide complexes, 
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similar to the viral cell complex. For example, galactofucan (GFS), a sulfated polysaccharide isolated 
from the Tasmanian seaweed Undaria pinnatifida, inhibited HSV-1 (IC50 = 32 μg/mL) and HSV-2 
(IC50 = 0.5 μg/mL) activity by preventing binding and entry of virus into the host cells [51]. Thus, 
sulfated polysaccharides from certain seaweeds mimic the cell sulfates and block the entry of viruses 
into the cells [52]. Additionally, Bourgougnon et al. (1993) [21] reported that an aqueous extracts of 
the red alga Schizymenia dubyi extracted a higher sulfate content and was effective in inhibiting HSV-1 
replication at EC50 = 2.5–80 μg/mL, without a cytotoxic effect. Similarly, in the present study, the  
C. crispus fractions extracted by carbohydrases (C1 and C3) had the higher content of sulfate  
(Figure 5b, 11.7% ± 0.1% and 11% ± 0.1%, respectively), which could have contributed to the higher 
antiviral activity observed (Table 3). In C. fragile, the fraction obtained from protease (P1) was more 
conducive for MOI = 0.01 ID50/cells (Table 3). This could be due to a higher percentage of glucose 
(55.92% ± 0.45%) in the protease (P1) fraction of C. fragile (Table 2). Previous reports validated the 
antiviral potential of glucose derivatives including 2-deoxy-D-glucose, uridine 5′-diphosphate glucose, 
and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (PGG) isolated from plant extracts [53,54]. Xiang et al. 
(2011) [55] reported that a glucose derivative, 1,2,4,6-tetra-O-galloyl-β-D-glucose (1246TGG), 
isolated from the traditional Chinese medicinal plant Phyllanthus emblica L. (Euphorbiaceae) 
1246TGG exhibited antiviral activity against Herpes simplex virus Type 1 (HSV-1) and Type 2 (HSV-2) 
infections by inactivating HSV-1 particles, thus preventing viral attachment and penetration [55]. 
Further, these sugar molecules have been shown to block the synthesis of the main glycosylated 
polypeptide of HSV [56]. In CF, the fraction obtained from carbohydrases (C1) also showed 
significant anti-HSV-1 activity (p < 0.0001) Taken together, these results indicate that enzyme-assisted 
extraction is an efficient method to increase the yield from the selected red and green seaweeds  
C. crispus and C. fragile. Additionally, the enzymatic hydrolysates showed enhanced protection to 
Vero cells against a HSV-1 challenge with no observed cytotoxicity.  
4. Materials and Methods 
4.1. Seaweeds 
A cultivated strain of the red alga C. crispus (CC) was a kind gift from Acadian Seaplants Limited, 
Nova Scotia, Canada. The green seaweed C. fragile was collected in Nova Scotia, Canada. One 
kilogram of freshly harvested seaweed was freeze-dried and ground to a powder (0.4 mm, mesh size) 
using a micro Wiley mill, standard model 3 (Arthur H Thomas Co., Philadelphia, PA, USA). The 
biomass obtained was stored at −20 °C until used. 
4.2. Extraction of Seaweeds 
4.2.1. Acid Extraction  
Acid hydrolysis was performed using the methods described by Defer et al. (2009) [57], with minor 
modifications. Two experiments were performed, using 10 mg of ground seaweed. The hydrolyzed 
materials were extracted in 5 mL of hydrochloric acid (1N HCL) in a heat block (100 °C) for 2 or 5 h. 
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Composition of the hydrolyzed extracts was analyzed after neutralizing with sodium hydroxide  
(5 mL NaOH).  
4.2.2. Enzyme Extraction 
Four commercial enzymes from Novozyme—cellulase (C1), β- glucanase (C2), ultaflo (C3), and 
proteases (Neutrase)—were used for the extractions. Hydrolysis was performed as described by 
Hardouin et al. (2014) [2], with minor modifications. The extraction procedure is summarized in 
Scheme 1. Enzyme-assisted extraction was performed by adding ground seaweed powder (1 and 10 g 
of CC and CF, respectively) to 200 mL of distilled water. Enzymes were added at a concentration of 
0.5% and were placed in a 50 °C water bath for 3 h, after which the enzyme was denatured by raising 
the temperature to 90 °C for 15 min. The extraction process for C. crispus was modified (1 g of CC in 
200 mL of water) with two additional enzymes (C2 and C3) to overcome the interference of gelling 
agents present in its cell wall. The hydrolysates were centrifuged at 8000× g for 15 min at 20 °C to 
remove the undigested residue. The resulting supernatant was filtered, freeze-dried, weighed, and 
stored at −20 °C for further experiments. 
Addition of water to ground seaweeds 
(CC: 1g or CF:10 g made up to 200 mL in H2O) 
Temperature Adjustment 
Homogenization 
Enzyme addition,  
pH measurement (∆ 30 min)  
Incubation 
Enzyme Inactivation 
3 h, 50 °C 
Filtration 
20 min, 90 °C 
Centrifugation 
20 min, 8000× g 
Enzymatic Seaweed Hydrolysate 
 
Scheme 1. Schematic representation of seaweed extraction process. 
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4.2.3. Water Extraction 
The water extract served as a control in all experiments. Water extract was produced by adding 1 
and 10 g of freeze dried seaweed powder (CC and CF, respectively) to 200 mL of distilled water and 
extracted at 50 °C for 3 h. 
4.3. Analysis of Chemical Composition of Extracts of Seaweed 
Neutral sugars in the extract were determined by the phenol-sulphuric acid colorimetric method, as 
described by Dubois (1956) [58] using anhydrous D-glucose (0–100 μg/mL) as the standard. The 
uronic acid content was quantified using the meta-hydroxy-di-phenyl (MHDP) method [59] with 
gluconic acid as the standard. Following acid hydrolysis of the soluble polysaccharides, the free 
sulfates were measured by the Azure A method [60]. For this estimation, sulfated dextran (17%)  
(0–100 μg/mL) was used as the standard. The bicinchinonic acid colorimetric method (BCA) [61] with 
a Micro BC assay kit (cat. UP75860C, INTERCHIM) was used to measure the protein content. For the 
protein estimation, Bovine Serum Albumin (0–100 μg/mL) was used as the standard. Total ash was 
determined by incinerating the ground seaweeds at 550 °C for 16 h, followed by 900 °C for 2 h.  
4.4. Analysis of Carbohydrates in the Seaweed Hydrolysates 
High-performance anion-exchange chromatography (HPAEC) (Dionex, Sunnyvale, CA, USA) was 
used to determine the composition of carbohydrates in the extracts. The extracts were hydrolyzed with 
hydrochloric acid (1M) for 48 h at 100 °C. The hydrolysates obtained were neutralized with sodium 
hydroxide (1 M) and then filtered for analysis. An analytical column (CarboPac PA1, 4 × 250 mm) 
was used and the elution (1 mL/min and 110 bars) was carried out under alkaline conditions. The 
eluents used were: Milli-Q water (A), 100 mM NaOH (B), and 100 mM NaOH + 1M NaOAc (C). The 
injection volume was set to 2 μL and following elution program was used: 20 min isocratic (A/B 
80:20), 5 min linear gradient (from C 100%), followed by 5 min isocratic conditions (C, 100%) and  
re-equilibrium for 20 min at isocratic conditions (A/B, 80:20). Carbohydrates were detected by pulsed 
amperometry with a detector composed of a silver standard electrode and a gold working electrode. 
Commercially available reference compounds (e.g., ribose, glucose, rhamnose, galactose, arabinose, 
xylose, mannose, fructose, guloheptose, and glucuronic acid) were used as internal standards. The 
chromatograms were analyzed using Chromeleon® software (Dionex, Sunnyvale, CA, USA). 
Carbohydrates were identified and quantified by using calibration curves of internal standards (50 µM). 
4.5. Determination of Antiviral Activity 
4.5.1. Cells and Viruses 
The African green monkey kidney cell line (Vero, ATCC CCL-81) was used for Herpes simplex 
Type 1 (HSV-1) replication. The Eagle’s minimum essential medium (MEM, Eurobio, Courtaboeuf, 
France), supplemented with 8% fetal calf serum (FCS, Eurobio Courtaboeuf, France) and 1% 
antibiotics PCS (10,000 IU/mL penicillin, 25,000 IU/mL colimycin, 10 mg/mL streptomycin, Sigma, 
Saint-Quentin Fallavier, France) was used as the culture medium. The virus stock of HSV-1, a  
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wild-type strain 17 (sensitive to acyclovir), was a kind gift from Agut (Laboratoire de Dynamique, 
Paris, France). 
4.5.2. Cytotoxicity of Seaweed Hydrolysates 
The cytotoxicity of the seaweed extracts was tested on the Vero cell/HSV-1. Briefly, the cell 
suspensions (3.5 × 105 Vero cells/mL) were incubated with the seaweed hydrolysates (1–200 μg/mL,  
4 wells per concentration). Each dilution (50 μL) was made in Eagle’s MEM with 8% FCS, dispensed 
in 96-well (Nunclon, Intermed, Saint-Quentin Fallavier, France) micro-test III tissue culture plates, and 
incubated at 37 °C for 72 h with an atmosphere of 5% CO2. The culture medium, without the extract, 
served as the control. Cells were observed daily under a phase-contrast microscope to establish the 
minimum concentration of hydrolysate required to induce alternations in cell morphology (e.g., 
swelling, shrinkage, granularity, and floating). Cytotoxicity, based on cell viability, was determined using 
the neutral red dye assay [62]. Absorbance was read using a multi-plate spectrophotometer (Packard 
Spectra Count™) at 540 nm. The 50% cytotoxic concentration (CC50) of a given extract (expressed as 
percentage) was defined as the concentration that reduced the absorbance of treated cells to 50% of 
that of the untreated control. This was calculated as [(ODc) C − (ODc) MOCK/(ODc) C] × 100, where 
(ODc)C and (ODc) MOCK were the OD (optical density) values of the untreated cells and treated 
cells, respectively [63].  
4.5.3. Antiviral Activity of Seaweed Hydrolysates 
The selected seaweed hydrolysates (1–200 μg/mL, 50 μL) were diluted in Eagle’s MEM containing 
8% FCS and incubated (37 °C, 5% CO2) with cellular suspensions (3.5 × 105 Vero cells/mL, 100 μL) 
in 96-well plates. The cells were infected with a virus cell suspension (50 μL) at two MOIs of 0.01 and 
0.001 ID50/cells. MEM medium with 8% FCS (50 μL) was added to the mock treatments. Following 
incubation (72 h), the antiviral activity was evaluated by the neutral dye method [62]. The anti-herpetic 
compound Acyclovir (9-(2-hydroxyethoxymethyl guanine) (Merck, Whitehouse Station, NJ, USA), a 
commercial HSV-1 inhibitor, served as the positive control. Results of antiviral activity were 
expressed as effective antiviral concentration (EC50). The percentage of cell protection against the viral 
infection (%P) was calculated using the following formula: 
[((ODt) virus − (ODc) virus)/((ODc) MOCK − (ODc) virus)] × 100  
where (ODt) virus was the OD (optical density) of the test sample, (ODc) virus was the OD of the 
virus-infected control (no samples), and (ODc) MOCK was the OD of the mock-infected control. The 
concentration of seaweed hydrolysate, which provided 50% protection to virus-infected cells, was 
determined from a dose-response curve using linear regression [62,63]. 
4.6. Statistical Analysis 
The experiment was set up in a completely randomized design. In quantification assays, linear 
regression analysis was carried out for standards using a scatter plot (Microsoft excel®, 2012). Results 
are expressed as mean ± standard deviation (SD). Each experiment was repeated three times and was 
conducted in triplicate. The data were analyzed using ANOVA, with a P value < 0.05 using the Proc. 
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mixed procedure, of the SAS Institute, Inc. software version 9.3 (SAS Institute, Inc., Cary, NC, USA). 
When significant effects of treatments were found, multiple means comparison was carried out using 
Tukey’s analysis with a 95% confidence interval and α = 0.05 (α—level of significance) to 
differentiate treatment means. 
5. Conclusions 
The green and red seaweeds used in this study, C. fragile and C. crispus, were subject to enzymatic 
hydrolysis. The extracts produced were tested for their antiviral activity. C. crispus was characterized 
by higher levels of protein and sulfate and C. fragile had a higher amount of neutral sugar and ash. The 
commercial enzymes tested showed higher yields of bioactive materials in both seaweeds. Since 
enzyme extraction is solvent-free, the hydrolysates obtained were of food grade and could be easily 
utilized in the cosmetics and food industries. Furthermore, extracts obtained from enzyme-assisted 
hydrolysis exhibited antiviral activity with EC50 values in the range of 77.6–129.8 μg/mL for CC and 
36–52 μg/mL for CO, at a MOI of 0.001 ID50/cells without cytotoxity. Additionally, even at higher 
MOI (0.01 ID50/cells), the enzymatic extracts from proteases (P1) and carbohydrases (C1 and C3) 
revealed significant antiviral activities. Ion exchange chromatography of extracts identified the 
presence of five simple sugars. The percentage of glucose was significantly higher in the enzymatic 
extract (P1) of both seaweeds tested. Interestingly, derivatives of glucose have been reported as  
anti-HSV compounds. In this regard, the tested seaweeds could be used in therapeutics to generate 
potential new antiviral drugs for humans. In summary, enzymatically produced extracts of C. fragile 
and C. crispus exhibited promising anti-HSV activity that could be used for novel, functional 
applications in pharmaceutical, nutraceutical, and functional food applications.  
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